Clinical Trial

A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study adopts a retrospective design. Patients enrolled will include those who received furmonertinib (treatment duration ≥1 month) between March 3, 2021, and December 31, 2024, with concurrent therapies permitted (e.g., radiotherapy, intrathecal chemotherapy, surgical interventions such as ventriculoperitoneal shunting). A retrospective analysis will be conducted to investigate the efficacy and safety of furmonertinib-based therapy (with or without other treatments) in EGFR-mutated NSCLC patients with leptomeningeal metastasis.
Trial Details
NCT Number NCT06926803
Lead Sponsor Qiming Wang
Conditions Lung Cancer (NSCLC), Leptomeningeal Cancer
Enrollment 500 participants
Start Date 2025-03-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-15